197 related articles for article (PubMed ID: 21094191)
61. Biodistribution, tumor uptake and efficacy of 5-FU-loaded liposomes: why size matters.
Fanciullino R; Mollard S; Correard F; Giacometti S; Serdjebi C; Iliadis A; Ciccolini J
Pharm Res; 2014 Oct; 31(10):2677-84. PubMed ID: 24752479
[TBL] [Abstract][Full Text] [Related]
62. Pharmacokinetics and tissue distribution of 5-fluorouracil encapsulated by galactosylceramide liposomes in mice.
Jin Y; Li J; Rong LF; Lü XW; Huang Y; Xu SY
Acta Pharmacol Sin; 2005 Feb; 26(2):250-6. PubMed ID: 15663907
[TBL] [Abstract][Full Text] [Related]
63. Preparation and evaluation of N(3)-O-toluyl-fluorouracil-loaded liposomes.
Sun W; Zhang N; Li A; Zou W; Xu W
Int J Pharm; 2008 Apr; 353(1-2):243-50. PubMed ID: 18155370
[TBL] [Abstract][Full Text] [Related]
64. Preparation and evaluation of chitosan based thermoreversible gels for intraperitoneal delivery of 5-fluorouracil (5-FU).
Depani BP; Naik AA; Nair HA
Acta Pharm; 2013 Dec; 63(4):479-91. PubMed ID: 24451073
[TBL] [Abstract][Full Text] [Related]
65. In vivo distribution of arsonoliposomes: effect of vesicle lipid composition.
Zagana P; Haikou M; Klepetsanis P; Giannopoulou E; Ioannou PV; Antimisiaris SG
Int J Pharm; 2008 Jan; 347(1-2):86-92. PubMed ID: 17689900
[TBL] [Abstract][Full Text] [Related]
66. Optimization of liposomal topotecan for use in treating neuroblastoma.
Chernov L; Deyell RJ; Anantha M; Dos Santos N; Gilabert-Oriol R; Bally MB
Cancer Med; 2017 Jun; 6(6):1240-1254. PubMed ID: 28544814
[TBL] [Abstract][Full Text] [Related]
67. Preclinical evaluation of novel, all-in-one formulations of 5-fluorouracil and folinic acid with reduced toxicity profiles.
Stutchbury TK; Vine KL; Locke JM; Chrisp JS; Bremner JB; Clingan PR; Ranson M
Anticancer Drugs; 2011 Jan; 22(1):24-34. PubMed ID: 20881836
[TBL] [Abstract][Full Text] [Related]
68. Preparation and characterization of 5-fluorouracil-loaded PLLA-PEG/PEG nanoparticles by a novel supercritical CO2 technique.
Zhang C; Li G; Wang Y; Cui F; Zhang J; Huang Q
Int J Pharm; 2012 Oct; 436(1-2):272-81. PubMed ID: 22721846
[TBL] [Abstract][Full Text] [Related]
69. Development of a liposomal formulation of the natural flavonoid fisetin.
Mignet N; Seguin J; Ramos Romano M; Brullé L; Touil YS; Scherman D; Bessodes M; Chabot GG
Int J Pharm; 2012 Feb; 423(1):69-76. PubMed ID: 21571054
[TBL] [Abstract][Full Text] [Related]
70. Development of new promising antimetabolite, DFP-11207 with self-controlled toxicity in rodents.
Fukushima M; Iizuka K; Jin C; Zhang C; Hong M; Eshima K
Drug Des Devel Ther; 2017; 11():1693-1705. PubMed ID: 28652707
[TBL] [Abstract][Full Text] [Related]
71. Evaluation of Anticancer Activity of Zhubech, a New 5-FU Analog Liposomal Formulation, against Pancreatic Cancer.
Ndemazie NB; Bulusu R; Zhu XY; Frimpong EK; Inkoom A; Okoro J; Ebesoh D; Rogers S; Han B; Agyare E
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901721
[TBL] [Abstract][Full Text] [Related]
72. Preparation of pegylated nano-liposomal formulation containing SN-38: In vitro characterization and in vivo biodistribution in mice.
Atyabi F; Farkhondehfai A; Esmaeili F; Dinarvand R
Acta Pharm; 2009 Jun; 59(2):133-44. PubMed ID: 19564139
[TBL] [Abstract][Full Text] [Related]
73. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice.
Mayer LD; Tai LC; Ko DS; Masin D; Ginsberg RS; Cullis PR; Bally MB
Cancer Res; 1989 Nov; 49(21):5922-30. PubMed ID: 2790807
[TBL] [Abstract][Full Text] [Related]
74. Development of a novel probe sonication assisted enhanced loading of 5-FU in SPION encapsulated pectin nanocarriers for magnetic targeted drug delivery system.
Dutta RK; Sahu S
Eur J Pharm Biopharm; 2012 Sep; 82(1):58-65. PubMed ID: 22634237
[TBL] [Abstract][Full Text] [Related]
75. In vitro and in vivo evaluation of injectable implants for intratumoral delivery of 5-fluorouracil.
Chen W; Wu Z; Yang H; Guo S; Li D; Cheng L
Pharm Dev Technol; 2014 Mar; 19(2):223-31. PubMed ID: 23432601
[TBL] [Abstract][Full Text] [Related]
76. Folic acid-modified liposomal drug delivery strategy for tumor targeting of 5-fluorouracil.
Moghimipour E; Rezaei M; Ramezani Z; Kouchak M; Amini M; Angali KA; Dorkoosh FA; Handali S
Eur J Pharm Sci; 2018 Mar; 114():166-174. PubMed ID: 29247686
[TBL] [Abstract][Full Text] [Related]
77. A Study of Liposomal Formulations to Improve the Delivery of Aquated Cisplatin to a Multidrug Resistant Tumor.
Zhao Y; May JP; Chen IW; Undzys E; Li SD
Pharm Res; 2015 Oct; 32(10):3261-8. PubMed ID: 25964047
[TBL] [Abstract][Full Text] [Related]
78. Peritoneal retention of liposomes: Effects of lipid composition, PEG coating and liposome charge.
Dadashzadeh S; Mirahmadi N; Babaei MH; Vali AM
J Control Release; 2010 Dec; 148(2):177-86. PubMed ID: 20800629
[TBL] [Abstract][Full Text] [Related]
79. Antitumor effect of intratumoral administration of fluorouracil/epinephrine injectable gel in C3H mice.
Yu NY; Orenberg EK; Luck EE; Brown DM
Cancer Chemother Pharmacol; 1995; 36(1):27-34. PubMed ID: 7720172
[TBL] [Abstract][Full Text] [Related]
80. Peri-tumor administration of 5-fluorouracil sol-gel using a hollow microneedle for treatment of gastric cancer.
Jung YS; Koo DH; Yang JY; Lee HY; Park JH; Park JH
Drug Deliv; 2018 Nov; 25(1):872-879. PubMed ID: 29608119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
